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Purpose
Standardisation of care opens the chance to further
improve the quality of care for children and adolescents
with JIA. We aimed to update our interdisciplinary, evi-
dence-based clinical practice guidelines for the treatment
of JIA. Our update is based on the existing German guide-
lines of 1999* and 2005* and 2008# (*published as book
chapters; #peer review publication in Clinical Research and
Practice in Pediatrics 2008; 220: 392 - 402).
Methods
We performed a systematic literature analysis (deadline:
15th January 2010) in PUBMED with the key words “juve-
nile idiopathic (rheumatoid) arthritis” and “therapy”. As
limits in PUBMED we used: humans, published in the last
3 years, all child 0-18 years, clinical trial. Studies were eval-
uated for quality of methodology. Studies relating to diag-
nosis of JIA, uveitis, vaccination, transition and rofexocibe
were excluded. Authors of the 2005 guideline and repre-
sentatives attended consensus conferences, held on 9th of
may 2007, 1st of August 2007 and 15th of January 2010 at
Düsseldorf respectively Krefeld, Germany. Conferences
were hosted by a professional moderator and were
attended by 95 % of the representatives who had been
named by interdisciplinary scientific societies. Scientific
societies and organisations represented paediatricians in
practice and hopistals, adult and pediatric rheumatologists,
orthopaedics, ophthalmologists, surgeons, physiothera-
pists, national and local support-groups for parents and
children. We edited a manuscript with core conclusions of
the studies. Statements were discussed and confirmed in a
Delphi method.
Results
The 2010 version of guideline inlcudes 15 statements.
Updated consensus statements and key notes regarding
drug therapy, symptomatic and surgical management of
JIA were compiled and judged strictly by the criteria of
Evidence-Based Medicine (EBM).
Conclusion
Many interventions in the treatment of JIA can now be
based on high level evidence as the number of randomized
controlled clinical trials is increasing: In a first step it is
recommended that JIA is treated with NSAR followed by
IATH and/or MTX. Other interventions such as the role
of biological agents, physiotherapy, arthroscopy, etc. are
discussed strictly on the basis of literature available. Com-
plementing these data with the long-standing experience
of caregivers allows to create recommendations that may
improve the quality of care for children and adolescents
with JIA.
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